Uterine Cancer Diagnostics Testing Market Size, Share And Global Trend By Type (Bloodtest, Endometrial biopsy, Imaging, Others), By End-user (Hospitals, Diagnostic centers, Cancer research centers, Others)And Regional Forecast, 2024-2032
KEY MARKET INSIGHTS
In December 2018, Samsung Medison Co., Ltd. received the U.S Food and Drug Administration (FDA) approval for the company’s HS50/HS60 Diagnostic Ultrasound System used for transvaginal ultrasound scanning. Obesity, diabetes, Cowden syndrome, increased consumption of tamoxifen and sedentary lifestyle are some of the prominent causes for developing uterine cancer. Women over age 50 years are more prone to uterine cancer. Endometrial biopsy is considered as the gold standard for diagnosis of endometrial cancer. According to the National Cancer Institute, as of 2019, there are an estimated 60,000 new cases of uterine cancer in the U.S. In some cases, uterine cancer leads to gestational trophoblastic disease.
Rising prevalence of uterine cancer is one of the significant drivers for the growth of global uterine cancer diagnostics testing market. According to the Canadian Cancer Society, in 2017, 7,300 women were diagnosed with uterine cancer in Canada alone. According to the Department of Health & Human Services, an estimated 11.0% of women between age 15-40 years are affected by endometriosis each year in the U.S. This combined with, rising prevalence of obesity as well as diabetes, growth in menstrual complications and rise in adoption of sedentary lifestyle is expected to further increase the prevalence of uterine cancer, which will eventually boost the demand for uterine cancer diagnostics testing during forecast period.
To gain extensive insights into the market, Request for Customization
However, complexities in biopsy procedure, high installations costs of imaging systems and lack of diagnostic infrastructure and shortage of healthcare resources including radiologists in emerging nations are restraining factors for the growth of global uterine diagnostics market.
Key Players Covered
Some of the major companies that are present in the global uterine cancer diagnostics testing market are F. Hoffmann-La Roche Ltd., Siemens Healthcare Private Limited, Abbott, Danaher, bioMérieux S. A., BD, and others.
SEGMENTATION
SEGMENTATION | DETAILS |
By Type | · Blood test · Endometrial biopsy · Imaging · Others |
By End-user | · Hospitals · Diagnostic centers · Cancer research centers · Others |
By Geography | · North America (USA and Canada) · Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe) · Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific) · Latin America (Brazil, Mexico and Rest of Latin America) · Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa) |
Among type, endometrial biopsy is anticipated to account for major share in the global uterine cancer diagnostics testing market owing to the higher adoption and cost associated with the technique.
Key Insights
Epidemiology of uterine cancer - for key countries, 2018
Market strategy of key players
Recent advancements in global uterine cancer diagnostics market
Key industry developments - mergers, acquisitions and partnerships, 2018
Regional Analysis
The global uterine cancer diagnostics testing market has been segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. North America is estimated to dominate the global uterine cancer diagnostics testing market in 2018 owing to the rise in prevalence of uterine cancer. According to the National Cancer Institute, in 2018, 63,230 new cases are diagnosed with uterine cancer in the U.S. alone. The incidence rate of uterine cancer is in the U.S., has increased by an estimated 1.3% from 2007-2017. Moreover, emphasis on early detection and prevention of cancer, improved accuracy in diagnostics due to technological enhancements in medical imaging techniques, rise in healthcare spending and various cancer awareness programs held by government is projected to be responsible for boosting the demand for global uterine cancer diagnostics testing market in the emerging countries of Asia Pacific.
Key Industry Developments
- In November 2018, GE Medical Systems received U.S Food and Drug Administration approval for the company’s Versana Premier, an Ultrasonic Pulsed Doppler Imaging System for detection of uterine cancer.
- In September 2018, GE Healthcare received U.S Food and Drug Administration approval for the company’s Voluson E6, Voluson E8, Voluson E10 pulsed Doppler imaging system.
- Ongoing
- 2023
- 2019-2022
-
Get in Touch with Us
-
US +1 833 909 2966 ( Toll Free )
-
